Bank of America Corp DE Purchases 105,666 Shares of Kemper Corporation $KMPR
Bank of America Corp DE increased its holdings in Kemper Corporation by 24.6% in the first quarter, acquiring an additional 105,666 shares and bringing its total to 535,144 shares valued at $16.35 million. Several other institutional investors also adjusted their stakes in Kemper, with the company trading at $27.41 and analysts setting new price targets. Kemper recently announced a quarterly dividend of $0.32 per share, and company insiders have also made significant share purchases.
What Are Wall Street Analysts' Target Price for Henry Schein Stock?
Henry Schein, Inc. (HSIC) has shown strong stock performance, outperforming the S&P 500 Index over the past year and year-to-date, though it lags behind the State Street SPDR S&P Health Care Services ETF (XHS). The company's mixed performance is attributed to strong internal sales and dental merchandise gains, despite shrinking profitability and softer U.S. dental demand. Analysts have a "Moderate Buy" consensus rating for HSIC, with a mean price target suggesting an 8.7% premium from current levels.
Zacks Research Has Bearish Estimate for SBC Q3 Earnings
Zacks Research has issued a bearish estimate for SBC Medical Group's Q3 2026 earnings, reducing its EPS forecast to $0.10 from $0.13, and also projected Q4 EPS at $0.10. This follows SBC Medical Group reporting Q2 EPS of $0.10, missing the consensus estimate of $0.12, although its revenue of $49.19 million surpassed expectations. The stock currently holds a "Hold" rating with an average price target of $8.50, while institutional investors own over 60% of the company.
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein, Inc. (HSIC) is showing improved growth across its core businesses and a better earnings outlook, with management raising its 2026 sales and earnings guidance. The company's Henry Schein One segment provides a recurring revenue stream, and a value creation plan aims to significantly boost operating income. Despite these positives, the investment case carries execution risks due to leverage, customer concentration, and competitive pressures, with its valuation trading at a discount to broader markets but above its five-year median.
Henry Schein, Special Olympics re-up partnership
Henry Schein, Inc. and Special Olympics have extended their partnership through 2030, continuing their efforts to enhance access to health screenings, education, and wellness resources for Special Olympics athletes globally. This collaboration, which started in 2018, involves Henry Schein donating oral health and medical care products for the Healthy Athletes program. The partnership also aims to empower healthcare providers to volunteer and improve their skills in caring for individuals with intellectual disabilities.
BTIG Adjusts Price Target on Henry Schein to $110 From $100, Maintains Buy Rating
BTIG has increased its price target for Henry Schein (HSIC) to $110 from $100, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm for the dental and medical product distributor. Henry Schein specializes in the distribution of healthcare products and services globally, with a significant portion of its sales in the United States.
Henry Schein and Special Olympics Renew Partnership Through 2030
Henry Schein and Special Olympics have renewed their partnership through 2030 to continue supporting the Healthy Athletes program. This collaboration aims to expand access to health screenings, education, and wellness resources for individuals with intellectual disabilities globally. Henry Schein will continue to donate oral health and medical care products for the program, which has provided over 2 million free health screenings since 1997.
Edwards Lifesciences stock holds steady as analysts see upside
Edwards Lifesciences (EW) stock is trading in the low-$90s with a moderate buy consensus and an average analyst price target of $100.27, suggesting a high-single-digit upside. Institutional investors are increasing their exposure to the company, and its transcatheter heart valve systems remain a key product line driving revenue and innovation. The stock's current performance shows steady gains, with analysts expecting it to approach or surpass the $100 mark.
Building a healthier future together: Henry Schein and Special Olympics renew partnership through 2030
Henry Schein and Special Olympics have renewed their partnership through 2030, reinforcing their commitment to providing health screenings, education, and wellness resources for athletes with intellectual disabilities globally. This collaboration, which began in 2018, involves Henry Schein donating essential oral health and medical care products for the Special Olympics Healthy Athletes® program, which has delivered over two million free health screenings worldwide. The extended partnership aims to continue empowering healthcare providers and expanding access to critical care for people with intellectual disabilities, who face significant health disparities.
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
Henry Schein, Inc. (HSIC) has raised its 2026 sales and earnings outlook following a strong second quarter characterized by accelerated internal growth and improved profitability. The company's net sales increased by 6.7% to $3.46 billion, and adjusted earnings per share exceeded estimates. This positive revision is driven by momentum across various segments and anticipated benefits from a value creation program targeting significant operating income improvement.
Empowered Funds LLC Has $851,000 Position in Henry Schein, Inc. $HSIC
Empowered Funds LLC significantly reduced its stake in Henry Schein, Inc. by 59.2% in the first quarter, now holding 11,551 shares valued at $851,000. Despite this, other institutional investors have acquired new positions or increased their holdings in the company. Analysts have issued various price targets and ratings for Henry Schein, with the stock currently holding an average "Hold" rating and a consensus target price of $92.27.
Buckland Partners Management Co LLC Makes New Investment in Henry Schein, Inc. $HSIC
Buckland Partners Management Co LLC has acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC), purchasing 12,400 shares valued at approximately $1.04 million during the second quarter. Other institutional investors have also adjusted their positions, with institutional ownership now standing at 96.62%. The company's recent earnings exceeded expectations, reporting $1.27 EPS against a $1.24 consensus and revenue of $3.46 billion, surpassing the $3.37 billion forecast.
Henry Schein stock holds near a 52-week high after a Buy upgrade
Henry Schein stock is trading near its 52-week high after Wall Street Zen upgraded its rating to Buy. The company reported strong Q2 2026 earnings, beating EPS estimates, and its fiscal year guidance is close to analyst expectations. Despite the upgrade, the broader analyst view remains "Hold" with a limited upside to the average price target.
How the U.K. VAT Ruling Could Reshape Align's 2026 Earnings Outlook
Align Technology (ALGN) is facing a new tax challenge in the U.K. following a July Upper Tribunal decision that overturned a VAT exemption for clear aligners, effective September 7, 2026. This ruling has resulted in an estimated $37.5 million liability for Align and adds a 20% VAT charge to its products in the U.K. without raising list prices. While the company plans to appeal, the issue is expected to further complicate its 2026 earnings outlook amidst existing pressures from foreign exchange rates and changing product mix, despite healthy international growth in clear aligner volume.
Henry Schein (NASDAQ:HSIC) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Henry Schein (NASDAQ:HSIC) from a "Hold" to a "Buy" rating. Despite this upgrade, the broader analyst consensus remains "Hold" with an average price target of $92.27. Henry Schein recently reported strong quarterly earnings, beating EPS estimates and showing a 6.7% revenue increase year-over-year, and issued positive fiscal 2026 EPS guidance.
How Henry Schein’s Strong Q2 Earnings and Higher 2026 Sales Outlook Will Impact Henry Schein (HSIC) Investors
Henry Schein, Inc. reported strong Q2 2026 earnings with increased sales and net income, leading management to raise its full-year 2026 sales growth guidance to 4.5% to 5.5%. This positive outlook reinforces the company's strategy of shifting towards higher-margin technology and specialty products, despite potential short-term risks from competitive pricing in consumables. Analysts are re-evaluating their forecasts, with some bullish predictions of earnings climbing to US$671 million by 2029, suggesting confidence in the company's cost savings and value creation plans.
How Henry Schein’s Strong Q2 Earnings and Higher 2026 Sales Outlook Will Impact Henry Schein (HSIC) Investors
Henry Schein (HSIC) reported strong Q2 2026 earnings, with increased sales and net income, leading management to raise its full-year 2026 sales growth guidance. This positive performance reinforces the company's strategy of shifting towards higher-margin technology and specialty products, despite ongoing competitive pricing pressures in consumables. The revised outlook supports the bullish earnings narrative, though execution risks for cost savings and value creation plans remain.
Henry Schein (HSIC) insider Bergman plans $3.18M sale under Form 144
Henry Schein, Inc. insider Stanley M. Bergman has filed a Form 144 notice to sell 35,257 shares of Common Stock, valued at an estimated $3.18 million, on or after August 14, 2026, through J.P. Morgan Securities LLC. These shares were acquired via a share swap in 1994. The filing also notes previous sales by Bergman and a family trust in June 2026.
HSBC Bank Plc Reports No Stabilisation in National Grid North America Inc's EUR 1.3 Billion Dual-Tranche Euro Bond Issue
HSBC Bank plc has confirmed that no stabilization activities were conducted for National Grid North America Inc's EUR 1.3 billion dual-tranche euro-denominated bond issue. The bond offering includes EUR 700 million at 3.643% notes due April 2031 and EUR 600 million at 4.268% notes due April 2037, both priced at 99.999. This regulatory disclosure indicates that the bonds traded without price-support intervention from HSBC, which acted as the Stabilising Manager.
Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
Cooper Companies (COO) shows strong growth potential due to CooperVision's premium lens and myopia-management leadership, coupled with CooperSurgical's robust women's health and fertility segments. Despite near-term challenges like Asia-Pacific weakness and tariff/FX pressures, the company's sustained market-share gains and high-growth franchises position it favorably. Analysts maintain a positive outlook, with expectations of improved earnings and revenue growth in the coming fiscal years.
Inovio (INO) Q2 2026 Earnings Call Transcript
Inovio (INO) discussed its Q2 2026 financial results and provided an update on its lead candidate, INO-3107, which has a PDUFA date of October 30, 2026. The company highlighted progress in regulatory reviews, commercial launch preparations, and positive Phase III results for VGX-3100 from its partner ApolloBio. Inovio also announced the expansion of its DPROT technology platform to include new rare disease targets, Fabry disease and hypophosphatasia.
Henry Schein Inc. stock outperforms competitors on strong trading day
Shares of Henry Schein Inc. (HSIC) increased by 1.75% to $90.74 on Wednesday, marking its second consecutive day of gains. This performance occurred during a mixed trading session where the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average fell by 0.04%.
Henry Schein's (NASDAQ:HSIC) Earnings Seem To Be Promising
Henry Schein's recent earnings report was unchanged, but underlying numbers suggest encouraging factors for investors. The company incurred a significant US$103m expense due to unusual items, which, if not repeated, could lead to higher profits next year. Analysts predict improved profitability, and the company's earnings per share increased by 10% last year, indicating strong earnings potential.
Henry Schein (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein (HSIC) reported strong Q2 2026 results with total net sales of $3.5 billion, a 6.7% increase, and non-GAAP diluted EPS of $1.27, up 15.5%. The company raised its full-year 2026 sales and non-GAAP EPS guidance, driven by accelerated internal local currency growth, expanded operating margins, and the initial benefits of value creation initiatives. Management highlighted the strong performance of its cloud-based technology solutions, own brands, and growth in the DSO segment, while also discussing plans for operational rigor and disciplined capital deployment.
Henry Schein Inc. stock outperforms competitors on strong trading day
Henry Schein Inc. (HSIC) stock rose 1.25% to $89.18 on Tuesday, outperforming the broader market which saw the S&P 500 Index (SPX) fall 0.32% and the Dow Jones Industrial Average (DJIA) fall 0.34%. This gain ended a three-day losing streak for the company's shares.
Should Henry Schein’s (HSIC) Upgraded 2026 Outlook and New Structure Require Action From Investors?
Henry Schein (HSIC) recently reported strong Q2 2026 results, raising its full-year sales growth guidance to 4.5%–5.5% and unveiling a new leadership structure and integrated global supply chain. While the upgraded outlook and new structure aim to improve efficiency and execution, they also introduce additional execution risk that investors should monitor. The company's narrative projects $14.9 billion revenue and $653.3 million earnings by 2029, suggesting a fair value in line with its current price, though some optimistic analysts foresee faster profitability growth.
Empowered Funds LLC Lowers Holdings in Henry Schein, Inc. $HSIC
Empowered Funds LLC significantly reduced its stake in Henry Schein, Inc. by 59.2% in the first quarter, selling 16,735 shares and retaining 11,551 shares valued at $851,000. Despite this, Henry Schein exceeded quarterly earnings expectations with $1.27 EPS and $3.46 billion in revenue, and institutional investors collectively own 96.62% of the company. Analyst sentiment remains mixed with a "Hold" consensus rating, though some firms like BTIG and Piper Sandler maintain "Buy" or "Overweight" ratings with higher price targets.
First Trust Advisors LP Invests $2.26 Million in Advance Auto Parts, Inc. $AAP
First Trust Advisors LP has initiated a new position in Advance Auto Parts, investing approximately $2.26 million for 42,916 shares. Despite this new investment, analysts maintain a cautious outlook on AAP, with an average "Hold" rating and a target price slightly above its current trading price. The company recently surpassed quarterly earnings expectations and maintained its fiscal 2026 EPS guidance while paying a quarterly dividend.
Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution
Henry Schein is transforming its business by embedding AI into customer-facing applications and internal operations, simplifying its leadership structure, and focusing on faster execution. CEO Fred Lowery outlined this ambitious strategy following stronger second-quarter results and a significant leadership reorganization. The healthcare distributor aims to evolve into a technology-enabled business, leveraging AI to improve productivity, deepen customer relationships, and capture market share while targeting over $200 million in operating improvements.
Should Henry Schein’s (HSIC) Upgraded 2026 Outlook and New Structure Require Action From Investors?
Henry Schein, Inc. (HSIC) reported strong Q2 2026 results, raising its full-year 2026 sales growth guidance to 4.5%–5.5% and unveiling a new leadership structure and integrated global supply chain. This move aims to improve efficiency and execution, supporting the company's shift towards higher-margin technology and specialty solutions. Investors should monitor how effectively management implements these changes and delivers on broader cost and value creation plans, as the upgraded outlook presents both opportunities and execution risks.
Should Henry Schein’s (HSIC) Upgraded 2026 Outlook and New Structure Require Action From Investors?
Henry Schein, Inc. reported strong Q2 2026 results, raising its full-year 2026 sales growth guidance to 4.5%–5.5% and unveiling a new leadership structure and integrated global supply chain. While this upgraded outlook supports near-term execution, it also introduces execution risk for investors to monitor. The company's investment narrative projects $14.9 billion revenue and $653.3 million earnings by 2029, with a fair value estimate of $88.07.
Dentsply Sirona investors brace for earnings amid Medline threat By Investing.com
Dentsply Sirona Inc. is preparing to report second-quarter earnings, facing investor scrutiny over its ability to counter competitive pressure from Medline's expansion into the dental market. Analysts forecast earnings of 35 cents per share and revenue of $889.2 million, representing a significant year-over-year decline. The company's focus on its return-to-growth strategy and leveraging its technology portfolio against potential consumables weakness will be key for investors.
Henry Schein Inc. stock underperforms Thursday when compared to competitors
Shares of Henry Schein Inc. (HSIC) fell 1.52% to $88.23 on Thursday, ending a four-day winning streak. This underperformance occurred during a dismal trading session where the S&P 500 Index declined by 0.18% and the Dow Jones Industrial Average dropped by 0.85%.
Barclays Adjusts Price Target on Henry Schein to $100 From $86
Barclays has adjusted its price target for Henry Schein (HSIC) to $100, up from the previous $86. This change reflects recent analyst activity around the company, which specializes in distributing healthcare products and services, primarily dental and medical equipment. The adjustment comes amid other recent price target changes from various financial institutions for Henry Schein.
FMR LLC discloses 6.6% Henry Schein (HSIC) stake in Schedule 13G filing
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 6.6% in Henry Schein, Inc. (HSIC) through a Schedule 13G filing. FMR LLC holds sole voting power over 6,786,663.10 shares and sole dispositive power over 7,553,900.88 shares, while Abigail P. Johnson has sole dispositive power over the same 7,553,900.88 shares. This filing indicates an investment purpose rather than an intent to control the company.
Citigroup Adjusts Price Target on Henry Schein to $112 From $100
Citigroup has adjusted its price target for Henry Schein (HSIC) to $112, up from the previous $100. This update follows a series of other analyst adjustments for Henry Schein, which specializes in distributing healthcare products and services. The company recently reported strong Q2 2026 earnings and raised its fiscal year 2026 earnings guidance.
Barrington Research Adjusts Henry Schein PT to $104 From $97, Maintains Outperform Rating
Barrington Research has increased its price target for Henry Schein (HSIC) to $104 from $97, while reaffirming an "Outperform" rating on the stock. This adjustment comes amidst several other analyst revisions for Henry Schein, indicating ongoing analyst attention to the company's performance. The article also provides a brief overview of Henry Schein's business, which specializes in distributing healthcare products and services.
Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?
Henry Schein, Inc. (HSIC) recently hit a new 52-week high of $92.18, with shares up 2.6% over the past month and 17.9% year-to-date. The company has consistently beaten earnings estimates, reporting strong EPS and revenue growth. With a Zacks Rank of #2 (Buy) and favorable valuation metrics, analysts suggest there might still be room for the stock to appreciate further.
HENRY SCHEIN, INC. : JEFFERIES RAISES TARGET PRICE TO $95 FROM $80
Jefferies has increased its target price for HENRY SCHEIN, INC. (HSIC.O) shares to $95 from the previous $80. This update was reported by Reuters on August 5, 2026. The article itself is a brief announcement of this change.
Henry Schein Q2 2026 Earnings: Margin Gains Support Higher Guidance
Henry Schein reported strong Q2 2026 results with net sales up 6.7% and GAAP diluted EPS rising to $0.82, driven by internal growth, improved margins, and share buybacks. The company raised its FY2026 guidance for sales growth, non-GAAP diluted EPS, and Adjusted EBITDA growth, signaling sustained momentum. However, investors are advised to monitor cash conversion, rising short-term borrowings, and the gap between GAAP and non-GAAP guidance.
Henry Schein, Inc. Stock 12‑Month Price Target Raised to $91.69, Implies 6% Upside
Analysts have raised the average 12-month price target for Henry Schein, Inc. (HSIC) stock to $91.69, up from $89.62, implying a potential 6% upside from its Aug. 3 closing price. The consensus rating among 20 analysts remains a "Buy," with forecasts ranging from $64 to $105 per share.
Guardian Pharmacy Services opens long-term care (LTC) pharmacy in Lexington
Guardian Pharmacy Services has opened its first physical location in Kentucky, Guardian Pharmacy of Kentucky, in Lexington. This new state-of-the-art facility will serve residents in various long-term care communities across the state, enhancing service delivery and providing specialized medication management. The expansion aims to meet the growing demand for LTC pharmacy services in Kentucky, leveraging a unique business model that combines local leadership with centralized corporate support.
Henry Schein Inc. stock outperforms competitors on strong trading day
Shares of Henry Schein Inc. (HSIC) rallied 3.01% to $89.11 on Tuesday, outperforming the broader market as the S&P 500 Index rose 1.79% and the Dow Jones Industrial Average gained 1.71%. This marks the third consecutive day of gains for the stock.
Henry Schein, Inc. | HSIC Stock Price & Real-time Quotes
This article provides real-time stock price and financial information for Henry Schein, Inc. (HSIC). It details the current stock price, daily performance, market capitalization, trading volume, and key financial metrics. The page also includes an overview of related news, podcasts, and company profile information for investors.
Henry Schein (Nasdaq: HSIC) lifts Q2 2026 sales to $3.46B and EPS to $0.82
Henry Schein, Inc. reported strong Q2 2026 financial results with net sales increasing to $3,458 million and diluted EPS reaching $0.82, up from $0.70 in Q2 2025. The growth was observed across all segments, with Global Distribution and Value-Added Services leading the way. The company also detailed its debt position, ongoing 2024 restructuring plan, and share repurchase activities.
Henry Schein beats Q2 estimates, raises full-year guidance
Henry Schein Inc. reported strong second-quarter results, exceeding analyst expectations for both earnings per share and revenue. The healthcare solutions provider also raised its full-year adjusted EPS guidance and total sales growth outlook, citing sustained momentum across its businesses and solid operational execution. The company's internal sales, particularly in Global Dental Distribution merchandise, saw significant growth.
Henry Schein, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026
Henry Schein, Inc. reported strong financial results for the second quarter and first six months of 2026. For the second quarter, sales increased to USD 3,458 million and net income rose to USD 94 million, with diluted EPS at USD 0.82. The company also saw significant growth over the six-month period, with sales reaching USD 6,826 million and net income at USD 201 million, demonstrating a positive performance trend.
Henry Schein Releases Q2 2026 Financial Results
Henry Schein, Inc. announced its Q2 2026 financial results, with non-GAAP diluted earnings per share of $1.27, slightly exceeding the analyst forecast of $1.26. The company reported revenue of $3.46 billion, a 6.7% increase year-over-year, driven by strong performance in its Global Distribution and Value-Added Services segment. Management provided an adjusted EPS guidance range of $5.29 to $5.39 for fiscal year 2026.
Grainger's Q2 diluted per-share earnings rise 20.5% to $12.01
Grainger (NYSE: GWW) reported strong second-quarter 2026 results, with net sales increasing 10.3% to $5.0 billion and diluted earnings per share (EPS) rising 20.5% to $12.01. The company's operating margin improved to 16.1%, and it generated $333 million in free cash flow, returning $341 million to shareholders. Grainger has raised its full-year 2026 guidance for net sales and adjusted diluted EPS, reflecting continued strong performance despite geopolitical uncertainties.
Did Henry Schein Inc (HSIC) Just Beat EPS Estimates with Q2 Earnings? GF Score: 81/100, 2.7% Overvalued
Henry Schein Inc (HSIC) reported strong Q2 2026 financial results, surpassing analyst expectations with a 6.7% increase in total net sales and robust growth in both GAAP and non-GAAP EPS. The company's CEO, Fred Lowery, expressed confidence, leading to an upward revision of fiscal guidance for 2026. Despite being slightly overvalued according to its GF Value, Henry Schein maintains a strong GF Score of 81/100, indicating solid financial health and operational efficiency.
